Indications
Capivasertib is a kinase inhibitor indicated for use in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer. This applies to patients whose tumors have one or more PIK3CA/AKT1/PTEN alterations as detected by an FDA-approved test, and who have experienced disease progression on at least one endocrine-based regimen in the metastatic setting, or recurrence on or within 12 months of completing adjuvant therapy.
Dosage and Administration
-
Patient Selection: Select patients for treatment of HR-positive, HER2-negative advanced or metastatic breast cancer based on the presence of one or more of the following genetic alterations in tumor tissue: PIK3CA, AKT1, or PTEN.
-
Recommended Dosage: The recommended dose is 400 mg administered orally twice daily (with or without food) for 4 consecutive days, followed by 3 days off.
Specifications
160mg × 64 tablets/box
Reviews
There are no reviews yet.